During antifungal screening of some plant metabolites (PM), tested at different concentrations against human pathogenic fungi (dermatophytes) Epidermophyton floccosum, Microsporum audouinii, M. nanum, M. canis, M. gypseum, Trichophyton mentagrophytes, T. rubrum, T. violaceum and T. tonsurance. The plant metabolites of Trachyspermum ammi was found to be most effective. The minimum inhibitory concentration of the PM was found to be 0.1 microl/ml at which PM showed fungistatic action. The minimum fungicidal concentrations (MCCs) of the PM were found to be 0.2 microl/ml against human pathogenic fungi. The PM at MCCs showed heavy doses of inoculum potential and its activity did not expire even up to 72 months of storage. The gas liquid chromatographic (GLC) analysis of the oil indicated it to be a mixture of 4 minor (a-pinene, camphene, g-terpene, p-cymene) and 1 major (thymol) components. On comparing MIC of the metabolites with that of prevalent synthetic antifungal drugs, the metabolites was found more effective. Moreover, PM did not exhibit any adverse effect on mammalian skin up to 1.0% concentration. Further, the PM of Trachyspermum ammi was standerdized and formulated in the form of ointment and trialed clinicaly in MLN Medical college, Allahabad. 30 patients were selected, showing positive potassium hydroxide (KOH) results at the start of the trial. Patients were diagnosed as either tinea corporis, tinea cruris or tinea pedis. All patients were treated with ointment twice in a day for 4 week. At the end of medication, 30.0% of patients recovered complete cure, 45.0% showed significant improvement from the disease. No KOH negative cases of relapse were observed when patients were reexamined after two month following the end of treatment thereby, denoting the absence of relapse. The ointment showed maximum activity, was also found cost effective (INR. 1.0/gm), had long shelf life (72 month) and showed absence of any adverse effects. Thus , the plant metabolites (PM) of Trachyspermum ammi could be used as potential sources of antifungal agent after undergoing successful multicentre clinical trial. Which is in progress.
Full conference title:
The 15 th Congress of the International Society for Human and Animal Mycology
- ISHAM 15th (2003)